Probiotics for prophylaxis of vulvovaginal candidiasis relapses: Results of the international multicenter open-label REVOLACT study
Objective. To evaluate efficacy and safety of L. casei rhamnosus Doderleini strain (lactogynal, vaginal capsules), for prevention of recurrences of vulvovaginal candidiasis in the multicenter international multicenter open-label REVOLACT study. Subject and methods. After antimycotic therapy using sertaconazole (zalain, suppository 300 mg once and 2% cream 2 times a day for 8 days), female patients from main group (74 women) received intravaginal lactobacillus lactogynal within 21 days; the comparison group (80 women) of patients did not receive any probiotics. The period of dynamic observation of patients was 5 months, during which the registration of recurrences of vulvovaginal candidiasis (reporter and laboratory confirmed) was conducted. Results. Results demonstrate the effectiveness of combined therapy using sertaconazole (zalain, suppository 300 mg once and 2% cream 2 times a day for 8 days) followed by the application lactogynal within 21 days to prevent recurrence of vulvovaginal candidiasis compared to monotherapy with sertaconazole (zalain, suppository 300 mg once and 2% cream 2 times a day for 8 days). Time before relapse of vulvovaginal candidiasis after therapy with sertaconazole in the lactogynal group was 148.45±2.04 days and 137.40±4.41 days in the comparison group. The incidence of vulvovaginal candidiasis in the lactogynal group was significantly lower: 12 patients (16.2%) vs. 24 patients (30%) in the comparison group (p <0.05). Conclusion. Study demonstrates the efficacy and safety of L. casei rhamnosus Doderleini culture (lactogynal, vaginal capsules) in the complex treatment of vulvovaginal candidiasis for the prevention of relapse.Bashmakova N.V., Volkova N.Yu., Gnatko E.P., Dankova I.V., Dobrokhotova Yu.E., Karahalis L.Yu., Maltseva L.I., Nadelyaeva Ya.G., Potapov V.A., Serova O.F., Suturina L.V., Tarasova M.A., Tatarchuk T.F.
Keywords
probiotic
relapse
vulvovaginal candidiasis
lactoginal
LCR35
Supplementary Materials
- Table 1. General characteristics of the examined women
- Table 2. Exacerbations of vulvovaginal candidiasis in all study visits
- Table 3. Absolute and relative risk of recurrent vulvovaginal candidiasis
References
1. Sherrard J., Donders G., White D., Jensen J.S. European IUSTI European (IUSTI/WHO) guideline on the management of vaginal discharge, 2011. Int. J. STD AIDS. 2011; 22(8): 421-9.
2. Russian Society of Dermatovenerologists and Cosmetologists. Clinical recommendations for management of patients with sexually transmitted infections and urogenital infections. Moscow: Business express; 2012. 112p. (in Russian)
3. Workowski K.A., Berman S.M. Centers for disease control and prevention sexually transmitted disease treatment guidelines. Clin. Infect. Dis. 2011; 53 (Suppl. 3): S59-63.
4. Rosa M.I., Silva B.R., Pires P.S., Silva F.R., Silva N.C., Silva F.R. et al. Weekly fluconazole therapy for recurrent vulvovaginal candidiasis: a systematic review and meta-analysis. Eur. J. Obstet. Gynecol. Reprod. Biol. 2013; 167(2): 132-6.
5. Savicheva A.M., Shipitsyna E.V. Recurrent urogenital vandidosis: features of diagnosis and treatment. Meditsinsky sovet. 2015; 9: 12-5. (in Russian)
6. Falagas M.E., Betsi G.I., Athanasiou S. Probiotics for prevention of recurrent vulvovaginal candidiasis: a review. J. Antimicrob. Chemother. 2006; 58(2):266-72.
7. Martinez R.C., Franceschini S.A., Patta M.C., Quintana S.M., Candido R.C., Ferreira J.C. et al. Improved treatment of vulvovaginal candidiasis with fluconazole plus probiotic Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14. Lett. Appl. Microbiol. 2009; 48(3): 269-74.
8. Kern A.M., Bohbot J.M., Cardot J.M. Traitement préventif de la candidose vulvovaginale récidivante par probiotique vaginal: résultats de l’étude observationnelle Candiflore. La Lettre du Gynécologue. 2012; 370: 34-7.
9. Linhares I.M., Summers P.R., Larsen B., Giraldo P.C., Witkin S.S. Contemporary perspectives on vaginal pH and lactobacilli. Am. J. Obstet. Gynecol. 2011; 204(2): 120. e1-5.
10. Paiva L.C., Vidigal P.G., Donatti L., Svidzinski T.I., Consolaro M.E. Assessment of in vitro biofilm formation by Candida species isolates from vulvovaginal candidiasis and ultrastructural characteristics. Micron. 2012; 43(2-3): 497-502.
11. Ribeiro F.C., de Barros P.P., Rossoni R.D., Junqueira J.C., Jorge A.O. Lactobacillus rhamnosus inhibits Candida albicans virulence factors in vitro and modulates immune system in Galleria mellonella. J. Appl. Microbiol. 2017; 122(1): 201-11. doi: 10.1111/jam.13324.
12. Davar R., Nokhostin F., Eftekhar M., Sekhavat L., Bashiri Zadeh M., Shamsi F. Comparing the recurrence of vulvovaginal candidiasis in patients undergoing prophylactic treatment with probiotic and placebo during the 6 months. Probiotics Antimicrob. Proteins. 2016; 8(3): 130-3. doi: 10.1007/s12602-016-9218-x.
13. Hanson L., VandeVusse L., Jermé M., Abad C.L., Safdar N. Probiotics for treatment and prevention of urogenital infections in women: A systematic review. J. Midwifery Women’s Health. 2016; 61(3): 339-55. doi: 10.1111/jmwh.12472.
Received 21.04.2017
Accepted 28.04.2017
About the Authors
Bashmakova Nadezhda, MD, professor, director of the Ural Research Institute for Maternity and Infancy. Russia, Yekaterinburg, Repina str. 1Volkova Natalia, head of the gynecological department of the Consultative and Diagnostic Center of Pechersky district, Kiev. 01042 Ukraine, Kiev, L. Ukrainka Boulevard, 36-V
Gnatko Elena, MD, Professor, City Maternity Hospital № 6. 02125, Ukraine, Kyiv, P. Zaporozhets str. 26-A
Dankova Irina, candidate of medical science, senior researcher, Research Department of Preservation of Reproductive Function,
Ural Research Institute for Maternity and Infancy. Address: Russia, Yekaterinburg, Repina str. 1
Dobrokhotova Yulia, MD, Professor, head of the Department of Obstetrics and Gynecology, N.I. Pirogov Russian National Research Medical University.
117997, Russia, Moscow, Ostrovityanova str. 1
Karakhalis Lyudmila Yurievna, MD, professor, Regional Clinical Hospital No. 2. 350012, Russia, Krasnodar, Krasniy Partizan str. 6/2
Maltseva Larisa, Head of the Obstetrics and Gynecology Department One, Kazan State Medical Academy. 420012, Russia, Kazan, Mushtari str. 11
Nadeliaeva Yana, Ph.D., researcher of the laboratory of gynecological endocrinology, Scientific Center for Family Health and Human Reproduction.
644003, Russia, Irkustk, Timiryazeva str. 16
Potapov Valentin, MD, Professor, City Maternity Hospital № 1. 49000, Ukraine, Dnepropetrovsk, Lenina str. 2
Serova Olga Fedorovna, chief physician of the Moscow Regional Perinatal Center. 143900, Russia, Moscow Region, Balashikha, sh. Enthusiasts, 12
Suturina Larissa Viktorovna, MD, professor, head of the reproductive department of the Scientific Center for Family Health and Human Reproduction.
644003, Russia, Irkutsk, Timiryazeva str. 16
Tarasova Marina Anatolievna, MD, Professor, D.O. Ott Scientific Research Institute of Obstetrics and Gynecology.
199034, Russia, St. Petersburg, Mendeleevskaya line, 3. E-mail: tarasova@ott.ru
Tatarchuk Tatyana Feofanovna, MD, Professor, City Clinical Endocrinology Center. 01034, Ukraine, Kyiv, Reitarskaya str. 22
For citations: Bashmakova N.V., Volkova N.Yu., Gnatko E.P., Dankova I.V., Dobrokhotova Yu.E., Karahalis L.Yu., Maltseva L.I., Nadelyaeva Ya.G., Potapov V.A., Serova O.F., Suturina L.V., Tarasova M.A., Tatarchuk T.F. Probiotics for prophylaxis of vulvovaginal candidiasis relapses: Results of the international multicenter open-label REVOLACT study.
Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2017; (6): 136-42. (in Russian)
http://dx.doi.org/10.18565/aig.2017.6.136-42
Similar Articles
